We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+12.07%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.23B
AUM Growth
+$191M
Cap. Flow
+$102M
Cap. Flow %
8.28%
Top 10 Hldgs %
30.7%
Holding
101
New
8
Increased
39
Reduced
39
Closed
6

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$18.2M
2
EXAS
Exact Sciences
EXAS
+$18.1M
3
MDT icon
Medtronic
MDT
+$13.5M
4
NVO
Novo Nordisk
NVO
+$13.3M
5
APLS
Apellis Pharmaceuticals
APLS
+$11.6M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$18.9M
2
UNH icon
UnitedHealth
UNH
+$18.4M
3
CI icon
Cigna
CI
+$11.2M
4
OSCR icon
Oscar Health
OSCR
+$9.64M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.15M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
51
Neurocrine Biosciences
NBIX
$16.8B
$8.27M 0.67%
71,750
-3,805
-5% -$522K
IONS icon
52
Ionis Pharmaceuticals
IONS
$9.46B
$7.81M 0.63%
195,000
+65,000
+50% +$3.02M
EVH icon
53
Evolent Health
EVH
$444M
$7.49M 0.61%
265,000
+215,000
+430% +$5.54M
CRL icon
54
Charles River Laboratories
CRL
$13.2B
$7.39M 0.6%
37,500
+3,500
+10% +$727K
TMDX icon
55
Transmedics
TMDX
$3.07B
$7.11M 0.58%
45,270
+31,770
+235% +$4.9M
IMVT icon
56
Immunovant
IMVT
$8.24B
$6.93M 0.56%
243,000
+112,500
+86% +$3.32M
BBIO icon
57
BridgeBio Pharma
BBIO
$16.6B
$6.82M 0.55%
268,000
+83,500
+45% +$2.19M
NRIX icon
58
Nurix Therapeutics
NRIX
$2.69B
$6.74M 0.55%
300,000
+125,607
+72% +$2.85M
ACHC icon
59
Acadia Healthcare
ACHC
$2.96B
$6.71M 0.54%
105,750
+65,926
+166% +$4.76M
VKTX icon
60
Viking Therapeutics
VKTX
$4.02B
$6.49M 0.53%
102,500
-12,500
-11% -$733K
BNTX icon
61
BioNTech
BNTX
$23.3B
$6.06M 0.49%
+51,000
New +$4.69M
EHC icon
62
Encompass Health
EHC
$12.4B
$5.9M 0.48%
61,000
+1,000
+2% +$89.9K
DXCM icon
63
DexCom
DXCM
$33.1B
$5.83M 0.47%
87,000
-30,000
-26% -$2.46M
SNDX icon
64
Syndax Pharmaceuticals
SNDX
$1.82B
$5M 0.41%
259,500
+31,000
+14% +$640K
EPIX
65
DELISTED
ESSA Pharma
EPIX
$4.88M 0.4%
804,649
-1,405
-0.2% -$7.72K
JANX icon
66
Janux Therapeutics
JANX
$1B
$4.85M 0.39%
106,847
– –
GERN icon
67
Geron
GERN
$949M
$4.54M 0.37%
+1,000,000
New +$4.55M
DNTH icon
68
Dianthus Therapeutics
DNTH
$6.25B
$4.11M 0.33%
+150,000
New +$4.18M
XNCR icon
69
Xencor
XNCR
$1.6B
$4.1M 0.33%
203,750
-15,000
-7% -$282K
MIRM icon
70
Mirum Pharmaceuticals
MIRM
$6.02B
$4.09M 0.33%
105,000
-29,250
-22% -$1.17M
IDYA icon
71
IDEAYA Biosciences
IDYA
$3.54B
$4.04M 0.33%
127,500
+74,000
+138% +$2.81M
TGTX icon
72
TG Therapeutics
TGTX
$7.52B
$4.01M 0.33%
171,500
-42,000
-20% -$917K
MRUS
73
DELISTED
Merus
MRUS
$3.97M 0.32%
79,500
-11,000
-12% -$574K
ALKS icon
74
Alkermes
ALKS
$8.29B
$3.72M 0.3%
133,000
-17,000
-11% -$453K
ANNX icon
75
Annexon
ANNX
$883M
$3.32M 0.27%
560,000
-340,000
-38% -$2.02M
1 2
3
4 5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2024 Portfolio in Review

As of Q3 2024, Rhenman & Partners Asset Management held 101 positions worth $1.23B, up 18% from $1.04B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $102M of net new capital in Q3 2024, opening 8 new positions and adding to 39 existing holdings. Its largest new stake was Novo Nordisk: 100,000 shares worth $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Elevance Health, an estimated $18.9M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2024 buy was Novo Nordisk: 100,000 shares worth $11.9M.
  • Rhenman & Partners Asset Management added most to Inspire Medical Systems in Q3 2024, an estimated $18.2M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2024 reduction was Elevance Health, cutting an estimated $18.9M.
  • Rhenman & Partners Asset Management fully exited Edwards Lifesciences in Q3 2024, selling an estimated $9.01M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $1.23B portfolio in Q3 2024.
  • Rhenman & Partners Asset Management opened 8 new positions and closed 6 in Q3 2024.
  • Rhenman & Partners Asset Management's portfolio value rose 18% quarter-over-quarter to $1.23B.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.